These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 22905595)
1. Early improvement of patients' condition during allergen-specific subcutaneous immunotherapy with a high-dose hypoallergenic 6-grass pollen preparation. Rajakulasingam K Eur Ann Allergy Clin Immunol; 2012 Jun; 44(3):128-34. PubMed ID: 22905595 [TBL] [Abstract][Full Text] [Related]
2. 3-years' long-term effect of subcutaneous immunotherapy (SCIT) with a high-dose hypoallergenic 6-grass pollen preparation in adults. Dominicus R Eur Ann Allergy Clin Immunol; 2012 Jun; 44(3):135-40. PubMed ID: 22905596 [TBL] [Abstract][Full Text] [Related]
3. Accelerated up-dosing of subcutaneous immunotherapy with a registered allergoid grass pollen preparation. Pfaar O; van Twuijver E; Hecker H; Boot JD; van Ree R; Klimek L Int Arch Allergy Immunol; 2013; 160(4):420-4. PubMed ID: 23183541 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sublingual immunotherapy with grass monomeric allergoid: comparison between two different treatment regimens. Quercia O; Bruno ME; Compalati E; Falagiani P; Mistrello G; Stefanini GF Eur Ann Allergy Clin Immunol; 2011 Dec; 43(6):176-83. PubMed ID: 22360134 [TBL] [Abstract][Full Text] [Related]
5. Specific immunotherapy in local allergic rhinitis: A randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy. Rondón C; Blanca-López N; Campo P; Mayorga C; Jurado-Escobar R; Torres MJ; Canto G; Blanca M Allergy; 2018 Apr; 73(4):905-915. PubMed ID: 29168570 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy. Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study. Vervloet D; Birnbaum J; Laurent P; Hugues B; Fardeau MF; Massabie-Bouchat YP; Aferiat-Derome A; André C Int Arch Allergy Immunol; 2007; 142(3):239-46. PubMed ID: 17114889 [TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study. Höiby AS; Strand V; Robinson DS; Sager A; Rak S Clin Exp Allergy; 2010 Jul; 40(7):1062-70. PubMed ID: 20642579 [TBL] [Abstract][Full Text] [Related]
10. Additional benefit of a third year of specific grass pollen allergoid immunotherapy in patients with seasonal allergic rhinitis. Williams A; Henzgen M; Rajakulasingam K Eur Ann Allergy Clin Immunol; 2007 Apr; 39(4):123-6. PubMed ID: 17523386 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study. Mirone C; Albert F; Tosi A; Mocchetti F; Mosca S; Giorgino M; Pecora S; Parmiani S; Ortolani C Clin Exp Allergy; 2004 Sep; 34(9):1408-14. PubMed ID: 15347374 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. Frew AJ; Powell RJ; Corrigan CJ; Durham SR; J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133 [TBL] [Abstract][Full Text] [Related]
13. Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber. Meyer W; Narkus A; Salapatek AM; Häfner D Allergy; 2013 Jun; 68(6):724-31. PubMed ID: 23621350 [TBL] [Abstract][Full Text] [Related]
14. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually. Panzner P; Petrás M; Sýkora T; Lesná I Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients. Rossi RE; Monasterolo G Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445 [TBL] [Abstract][Full Text] [Related]
16. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Kleine-Tebbe J; Ribel M; Herold DA Allergy; 2006 Feb; 61(2):181-4. PubMed ID: 16409193 [TBL] [Abstract][Full Text] [Related]
17. Towards evidence-based medicine in specific grass pollen immunotherapy. Calderon M; Mösges R; Hellmich M; Demoly P Allergy; 2010 Apr; 65(4):420-34. PubMed ID: 20028374 [TBL] [Abstract][Full Text] [Related]
18. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis. Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy with depigmented-polymerized mixed tree pollen extract: a clinical trial and responder analysis. Pfaar O; Robinson DS; Sager A; Emuzyte R Allergy; 2010 Dec; 65(12):1614-21. PubMed ID: 20645937 [TBL] [Abstract][Full Text] [Related]
20. Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide. Gadermaier E; Flicker S; Aberer W; Egger C; Reider N; Focke M; Vrtala S; Kundi M; Valenta R Int Arch Allergy Immunol; 2010; 151(1):17-27. PubMed ID: 19672093 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]